TransCode Therapeutics, Inc. (RNAZ) Stock Forecast
RNAZ analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $10.00 average of analyst targets
- Upside to target
- +488.2% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $1.54 – $14.76
RNAZ price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RNAZ earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$0.32 | −$0.32 | −$0.32 | −$1.63 | +80.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RNAZ revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | 0.0% | — |
RNAZ EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RNAZ EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$0.98 | −$0.98 | −$0.98 | −$0.32 | −$0.32 | −67.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RNAZ earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RNAZ beat in 2 of 9.
What analysts expect from RNAZ
The average price target is $10.00, 488.2% above the latest close of $1.70. For 2026 the average estimate is −$0.32 per share. TransCode Therapeutics beat the EPS estimate in 2 of the last 9 quarters.
Related: RNAZ income statement, RNAZ key metrics, RNAZ chart. See the RNAZ stock overview for the latest quote and news.
RNAZ forecast FAQ
What is TransCode Therapeutics's price target?
The average analyst price target for TransCode Therapeutics is $10.00, 488.2% above the latest close of $1.70.
When does TransCode Therapeutics report earnings?
TransCode Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does TransCode Therapeutics usually beat earnings estimates?
TransCode Therapeutics reported EPS at or above the analyst estimate in 2 of the last 9 quarters.